Rosemont Offers to Buy Aytu for $2.70 per Share at a 51.7% Premium
Key Facts
Aytu BioPharma announced on November 16, 2026, that it had entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings for $2.70 in cash for each outstanding share. The estimated total value is about $56 million on a fully diluted basis, using the treasury stock method. The price represents a 51.7% premium to the share’s November 13 closing price and a 41.1% premium to its 30-day volume-weighted average price before the announcement. The deal comes as the company reported quarterly revenue growth while shifting from net income to a net loss. Rosemont CEO Alok Sonig said the proposed acquisition “represents an important step in Rosemont’s U.S. growth strategy.”
The agreement will be carried out through a cash tender offer by a wholly owned Rosemont subsidiary to buy the outstanding shares, followed by a merger after which Aytu will become a wholly owned subsidiary of the buyer. Aytu’s board unanimously approved the deal and recommended that shareholders accept the offer and tender their shares. The agreement does not mean the acquisition is complete; the offer requires the tender of shares representing a majority of the outstanding shares, in addition to other conditions. Those conditions include the settlement or termination of certain outstanding warrants. Executives, directors and shareholders affiliated with Nantahala Capital Management and Stonepine Capital Management signed support agreements committing to tender their shares in the offer.
Aytu estimated net revenue for the first quarter of its fiscal 2027, ended September 30, 2026, at about $14.8 million, up 6.9% from $13.9 million in the same period of the prior fiscal year. Net results, however, turned to a loss of $3.9 million, compared with net income of $2.0 million in the first quarter of fiscal 2026. The current quarter’s results included a $0.3 million gain from derivative warrant liabilities. Adjusted EBITDA loss was $2.6 million, compared with a loss of $0.6 million a year earlier. The company attributed the wider loss on this measure mainly to continued marketing investments to promote EXXUA.
Revenue from the attention deficit hyperactivity disorder drug portfolio fell to $7.7 million in the quarter from $13.2 million in the same period of the prior fiscal year. Aytu attributed the decline mainly to reduced promotion as it shifted commercial resources toward EXXUA, and to competition from generic drugs. The portfolio’s decline contrasts with growth in overall revenue, which rose year over year during the quarter. Cash and cash equivalents totaled $25.5 million on September 30, 2026, compared with $26.3 million on June 30, 2026. The company also said it would not hold a conference call to discuss its financial results because of the pending merger with Rosemont.
Rosemont said it is a global pharmaceutical company focused on developing, manufacturing and supplying oral liquid medicines. It added that for nearly 60 years it has focused on creating alternative dosage forms for people who have difficulty swallowing tablets. Sonig described the deal as part of the company’s strategy to grow in the U.S. market and said the two companies’ expertise could support a platform for future growth. If the deal is completed, Aytu’s common shares will cease public trading. The company will remain listed until the procedures and conditions required to complete the acquisition are fulfilled.
Rosemont plans to launch the tender offer and file a Schedule TO within 10 business days of announcing the agreement. Aytu is expected to file a Schedule 14D-9 at approximately the same time the offer begins. Completion of the deal will then remain subject to the tender of shares representing a majority of the outstanding shares and the satisfaction or waiver of the other conditions. Rosemont expects to close the deal in late December 2026, subject to the satisfaction or waiver of the offer conditions. The launch of the offer and fulfillment of its conditions set out the next steps following the agreement announced on November 16.